Researchers show beneficial role of risk calculator in fighting progression of glaucomaOctober 17, 2005A new glaucoma risk calculator, which estimates a patient's risk of converting from high eye pressure, or ocular hypertension, to glaucoma, will help physicians determine whether to initiate therapy for patients. High eye pressure is the leading risk factor for glaucoma, and is the only modifiable one. If glaucoma is untreated, vision loss may continue, leading to blindness in some individuals. "The risk assessment idea came to me after studying the cardiovascular model which measures cholesterol to determine whether or not to initiate a statin for cholesterol lowering by assessing cholesterol, age, blood pressure, and other risk factors," said Robert N. Weinreb, M.D., Director of the Hamilton Glaucoma Center at University of California, San Diego and Distinguished Professor of Ophthalmology at the UCSD School of Medicine, and co-developer of the calculator. "The glaucoma risk calculator is a tool which allows doctors to better assess patient risk levels and, if needed, recommend treatment options that can help decrease the progression of glaucoma in patients with ocular hypertension." The risk calculator model will be reported at the American Academy of Ophthalmology annual meeting October 17 in Chicago, Ill., by Weinreb and Felipe A. Medeiros, M.D., Assistant Professor of Ophthalmology, at the UCSD Hamilton Glaucoma Center, lead author of the study demonstrating the risk calculator's effectiveness. Glaucoma, one of the leading causes of blindness, is an eye disease in which damage to the optic nerve located in the back of the eye results in loss of eyesight. About half of patients with glaucoma have ocular hypertension. Treatment depends on the degree or stage of the glaucoma. Physicians might not prescribe any treatment for ocular hypertension, for example, when increased pressure in the eye is minimal and no nerve damage is present. Routine monitoring of the patient's peripheral vision and of the appearance of the optic nerve may be sufficient. The glaucoma risk calculator is based on data collected from the multi-center National Eye Institute-sponsored Ocular Hypertension Treatment Study, which identified key patient risk factors (older age, high intraocular pressure, thinner central corneal thickness, larger vertical cup/disc ratio measurements and higher pattern standard deviation) predictive of disease progression from ocular hypertension to glaucoma. Although the OHT study results have provided a better understanding of the risk factors involved in the progression from ocular hypertension to glaucoma, physicians still face the challenge of combining these factors to assess individual patients. Drs. Weinreb and Medeiros have taken these key factors and examined them in an independent population of 126 untreated patients studied at the Hamilton Glaucoma Center. The Scoring Tool for Assessing Risk (STAR) a five-year glaucoma risk assessment tool determines an individual patient's overall risk of developing glaucoma. Physicians assess the six key risk factors and position their findings at various points on the tool, which can help them determine the risk of conversion from ocular hypertension to glaucoma within the next five years. "A collective assessment of these risk factors helps physicians identify those patients with elevated eye pressure who are more likely to progress to glaucoma and may benefit from early treatment," said Medeiros. By identifying patients with a higher chance of developing damage, the risk calculator can help physicians make decisions leading to more rational treatment of patients at highest risk, as well as discontinuing treatment and monitoring of patients at lowest risk. This could result in greater consistency in treatment, improving quality of care for patients with ocular hypertension and a decrease in patients who go on to develop glaucoma. University of California-San Diego |
|||||||||||||||||||||
| Related Glaucoma Current Events and Glaucoma News Articles 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. Cataract surgery helps AMD patients; steroid improves DME; online eye health forum This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums. Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T. Flynn, MD, Columbia University School of Medicine, discussing the ever-tougher challenges Eye M.D.s face in caring for the vision of the tiniest premature babies; and a report by Bradford W. Lee, MD, Stanford University School of Medicine, on barriers to glaucoma follow-up as perceived by patients in an urban, culturally diverse clinic. First in New York: Bionic technology aims to give sight to woman blinded beginning at age 13 A 50-year-old New York woman who was diagnosed with a progressive blinding disease at age 13 was implanted with an experimental electronic eye implant that has partially restored her vision. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness. Study predicts 40 percent increase in blindness in Nigeria by 2020 By 2020, 1.4 million Nigerians over age 40 will lose their sight, and the vast majority of the causes are either preventable or treatable, according to the Nigeria National Blindness and Visual Impairment Study Group. Unlikely genetic suspect implicated in common brain defect A genetic search that wound its way from patients to mouse models and back to patients has uncovered an unlikely gene critically involved in a common birth defect which causes mental retardation, motor delays and sometimes autism, providing a new mechanism and potentially improving treatment for the disorder. A drug-dispensing contact lens Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye. Clue to normal-tension glaucoma; herpes infection and corneal transplants The July issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes two studies that may influence clinical treatment of serious eye conditions. Cell's split personality is a major discovery into neurological diseases Researchers at the Université de Montreal (UdeM) and the Montreal Neurological Institute (MNI), McGill University have discovered that cells which normally support nerve cell (neuron) survival also play an active and major role in the death of neurons in the eye. More Glaucoma Current Events and Glaucoma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||